Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Povorcitinib Rollover Study in Hidradenitis Suppurativa
NCT06855498Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Feb 2025
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of povorcitinib in hidradenitis suppurativa (HS), sponsored by Incyte. Primary endpoint: Treatment-Emergent Adverse Events at 3 years. Started Feb 2025; status: recruiting.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06855498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855498.